All 63 donor-recipient pairs enrolled and treated according to protocol across multiple clinical centers Randomized, controlled Phase IIb trial ...
Top line data readout expected in late Q3/early Q4; INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with No ...
Last week Danish pharmaceutical company Novo Nordisk, the maker of the popular diabetes and weight-loss drugs Ozempic and ...
Psoriasis is a common, chronic, immune-mediated inflammatory disease. Many highly efficacious medications now exist for treating patients with psoriasis 1, but disease eventually recurs following ...
The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who ...
A large real-world clinical trial has found that a generative AI-powered support tool used to support frontline clinicians ...
TRIDENT is a global, open-label, two-arm trial; secondary end points include progression-free survival, overall radiologic ...
A large real-world clinical trial has found that a generative AI-powered support tool used to support frontline clinicians was safe and improved the quality of clinical decision-making, but did not ...
Novocure’ s shares stumbled nearly 20% after the company disclosed it failed to meet its primary endpoints in the TRIDENT ...
Zacks Small Cap Research on MSN
BDRX: Expanding phase 3 SERENTA trial into Canada; 73 patients enrolled thus far
By David Bautz, PhD NASDAQ: BDRX READ THE FULL BDRX RESEARCH REPORT Business Update Expanding Phase 3 Serenta Trial into Canada On June 29, 2026, Biodexa Pharmaceuticals, PLC (NASDAQ: BDRX) announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results